



Uptake of post-mastectomy immediate breast reconstruction in older women - A real-world analysis from the European Society of Breast Cancer Specialists (EUSOMA) certified breast centres

P.Y. Ng¹, R.M Parks, L. Marotti, A. Ponti, M. Tomatis, C. Aristei; G. Curigliano; J. De Vries, D. Santini, F. Sardanelli, P. Van Dam, I.T. Rubio, K.L. Cheung^{1,2}, M.J. Cardoso and the Eusoma Working Group.

¹Nottingham Breast Cancer Research Centre, University of Nottingham, UK

³School of Medicine, University of Nottingham, United Kingdom



EBCC PB-110

Background:

- Post-mastectomy immediate breast reconstruction (PMIBR) improves patients' quality of life and psychosocial well-being¹.
- Increasing worldwide proportion of older women living with breast cancer.
- Lower uptake of PMIBR in older women compared to younger women².

Methods:

- Real-world prospectively collected data from EUSOMA database.
- Older women are defined as age ≥ 70 years.
- Included: Female patients who had undergone mastectomy for primary breast cancer from 2017 to 2021.
- Excluded: delayed reconstruction and prophylactic mastectomy.

Results:

- A total of 16614 women were included, of which 12204 (73.5%) were younger and 4410 (26.5%) older women.
- Overall, 70% of younger women underwent PMIBR, while only 14% of older women underwent PMIBR as seen in Figure 1.
- Overall, the percentage of PMIBR in both older and younger women decreased as breast cancer stage increased from cTIS to cT4 as seen in Figure 2.
- Radiotherapy was an independent predictor for younger women not undergoing PMIBR, as was increasing nodal burden and receipt of neoadjuvant endocrine therapy. These factors were not significant in older women.




Figure 1. Percentage of women with and without PMIBR

		PMIBR	
		PMIBR rate for younger women (age <70) (%)	PMIBR rate for older women (age ≥ 70) (%)
Tumour Stage	cTIS	82.2	26.4
	cT1	76.7	20.5
	cT2	72.2	12.2
	cT3	56.6	6.5
	cT4	23.5 (p<0.001)	5.4 (p<0.001)
Nodal stage	cN0	75.2	16.0
	cN1	62.1	11.2
	cN2+	46.2 (p=0.034)	5.9 (p=0.065)
Treatment	No radiotherapy	78.3	15.8
	Radiotherapy	58.5 (p<0.001)	11.2 (p=0.484)
	No neoadjuvant therapy	74.7	14.9
	Neoadjuvant Chemotherapy	61.0 (p=0.245)	11.1 (p=0.230)
	Neoadjuvant Hormonal therapy	49.1 (p<0.001)	10.2 (p=0.552)

Figure 2. Multivariable analysis comparing tumour and treatment related factors with PMIBR rate (younger and older women analysed separately).

Conclusions:

- Only study which provides statistical evidence that there is a disparity in uptake of PMIBR between older and younger women
- Reasons for this disparity remain inadequately understood
- Further research to explore patient-, physician-, and system-associated factors

Contact details:
 @Kwokleungcheung
 Kwok_Leung.Cheung@nottingham.ac.uk

References:

¹Shiraishi M, Sowa Y, Tsuge I, Kodama T, Inafuku N, Morimoto N. Long-Term Patient Satisfaction and Quality of Life Following Breast Reconstruction Using the BREAST-Q: A Prospective Cohort Study. *Front Oncol.* May 23, 2022
²Chang-Azancot L, Abizanda P, Gijón M, Kenig N, Campello M, Juez J, et al. Age and Breast Reconstruction. *Aesthetic Plast Surg.* February 1, 2023

